Embedding probiotics and preparation and application thereof in improving hyperuricemia

Abstract

The application belongs to the technical field of food and drug microorganisms, and particularly relates to a kind of embedded probiotics and its preparation and application in improving hyperuricemia Embedded probiotics are coated by coating for probiotics;Wherein, the coating is a mixture of polydopamine and polylysine.The embedded probiotics (DY1@PLL) prepared by the application have higher tolerance and adhesion capacity to gastrointestinal juice than unencapsulated probiotics.DY1@PLL can significantly inhibit the activity of xanthine oxidase, adenosine dehydrogenase and inflammatory factors, and intestinal flora and serum metabolome in hyperuricemia mice, and has the potential to be applied to in vivo regulation of uric acid level, which provides a theoretical reference and guidance for the probiotic preparation of DY1@PLL for reducing hyperuricemia.

Description

Technical Field

[0001] This invention belongs to the field of food and pharmaceutical microbiology technology, specifically relating to an encapsulated probiotic, its preparation, and its application in improving hyperuricemia. Background Technology

[0002] Uric acid (UA) is a product of purine metabolism. When uric acid levels in the body are abnormally high, hyperuricemia (HUA) occurs. HUA is a major risk factor for gout. Currently, the prevention and treatment of HUA mainly include drug therapy and reducing the intake of foods containing purine compounds. Xanthine oxidase plays a key role in the biosynthesis of UA, catalyzing the oxidation of hypoxanthine to xanthine and then converting xanthine into UA. Allopurinol is an inhibitor of XOD, and although it can effectively lower UA levels, it is prone to causing side effects such as drug-induced liver injury. Therefore, research on effective and non-toxic therapeutic interventions for HUA is becoming a new area of ​​scientific exploration.

[0003] Probiotics are defined as live microorganisms that, when given in sufficient quantities, can provide one or more health benefits to the host. Lactic acid bacteria (LAB) are representative strains of probiotics with a long history of use and are widely considered safe. In recent years, many studies have also indicated that LAB has the potential to regulate purine metabolism and effectively reduce blood uric acid (UA) levels. However, LAB strains need to survive and reach a certain quantity in the host's gastrointestinal tract to possess a certain probiotic capacity. Studies have shown that the acid-base environment in the host's gastrointestinal tract can induce changes in the surface membrane potential and permeability of probiotics, leading to their death and inactivation. In addition, probiotics are also susceptible to temperature fluctuations during transportation and storage, resulting in a reduction in their numbers. Furthermore, due to the less-than-ideal adhesion of probiotics to the gastrointestinal mucosa, reduced bacterial colonization may weaken the expected therapeutic effect. Previous studies have mainly focused on the screening and modification of drug-resistant strains, but the screening or modification process is complex and difficult. Therefore, maximizing the stability of lactic acid bacteria during in vitro storage and processing and their in vivo survival rate after oral administration is a major challenge for functional strains. While technologies such as capsule formulation, polymer gel, and electrospinning have also been applied to probiotic encapsulation, issues arise. For example, microcapsules are difficult to control in shape, have large particle sizes, require various chemical reagents during packaging, and are complex to operate. The purpose of this invention is to provide a method for encapsulating probiotics, its preparation, and its application in improving hyperuricemia.

[0004] To achieve the above objectives, the present invention adopts the following technical solution:

[0005] An encapsulated probiotic, wherein the encapsulated probiotic is a probiotic coated with a coating; wherein the coating is a mixture of polydopamine and polylysine.

[0006] The probiotic is *Lactobacillus plantarum* DY1. It was obtained through preliminary screening in the laboratory and is currently deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO. 28810.

[0007] To elaborate further, 1.5 × 10 9 CFU Lactobacillus plantarum DY1 was added to Tris-HCl buffer containing 0.5 mg / mL dopamine, followed by 50 μL of polylysine solution (0.1-1 mg / mL). The mixture was stirred at room temperature for 30-45 min, and the precipitate was collected by centrifugation. The precipitate was then resuspended in Tris-HCl buffer containing 0.5 mg / mL dopamine, and 50 μL of polylysine solution (0.1-1 mg / mL) was added again. The mixture was reacted for 30 min, and the embedded strain was obtained by centrifugation.

[0008] A method for preparing the aforementioned encapsulated probiotics involves adding probiotics to a Tris-HCl buffer containing 0.5 mg / mL dopamine, adding 50 μL of a 0.1 mg / mL polylysine solution, stirring the mixture at room temperature for 30-45 min, centrifuging to collect the precipitate, resuspending the precipitate, adding more polylysine solution, and centrifuging again to obtain the encapsulated bacterial strain; wherein the concentration in the system is 1.5 × 10⁻⁶. 9 The CFU / mL bacterial culture contains 0.5 mg / mL of polydopamine, and the final concentration in the polylysine system is 0.1-1 mg / mL each time it is added.

[0009] To elaborate further, 1.5 × 10 9 CFU / mL probiotic solution was added to a 10mM Tris-HCl (pH 8.5) buffer containing 0.5 mg / mL polydopamine. Then, polylysine aqueous solution was added to the mixture and stirred at room temperature for 30-45 min to promote polymer diffusion. After the reaction, the mixture was centrifuged and washed. The sediment was then resuspended in Tris-HCl buffer (pH 8.5) and polylysine aqueous solution was added again. After centrifugation, the embedded strain DY1@PLL was obtained. The concentration of polydopamine in the system was 0.5 mg / mL, and the final concentration of polylysine added each time was 0.1-1 mg / mL.

[0010] An application of the aforementioned encapsulated probiotic, wherein the encapsulated probiotic is used in the preparation of functional foods or drugs related to the prevention and / or treatment of hyperuricemia; wherein the probiotic is *Lactobacillus plantarum* DY1, deposited on October 30, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO.28810, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, and classified as *Lactobacillus plantarum*.

[0011] A method for improving the relief of hyperuricemia, utilizing the encapsulated probiotics to improve the relief of hyperuricemia.

[0012] A probiotic agent for improving the relief of hyperuricemia, comprising the aforementioned encapsulated probiotics.

[0013] The bacterial strain DY1@PLL in the bacterial agent was cultured to the logarithmic growth phase.

[0014] Advantages of this invention:

[0015] This invention encapsulates probiotics using polydopamine and polylysine. Utilizing the uniform dendritic network structure and abundant amino groups on the PLL surface, it can covalently cross-link with DA and polymerization intermediates. This disrupts the non-covalent forces during DA self-polymerization, preventing the formation of aggregated particles and creating a uniform and stable outer layer, allowing the probiotics to be encapsulated. After encapsulation, the probiotics exhibit improved intestinal adhesion and in vitro gastrointestinal tolerance, significantly enhancing their physiological activity. Furthermore, the probiotic of this invention, DY1, when encapsulated and administered orally as a microecological preparation, reduces serum uric acid and XOD levels, lowers inflammatory factor levels, and is used to lower uric acid, alleviate hyperuricemia, and regulate intestinal flora and serum metabolic profiles in hyperuricemic mice. Attached Figure Description

[0016] Figure 1 This is an image of the probiotics successfully encapsulated according to the present invention.

[0017] Figure 2 This is a TEM image of Lactobacillus plantarum DY1 before embedding in this invention.

[0018] Figure 3 This is a TEM image of Lactobacillus plantarum DY1 after being embedded in the present invention.

[0019] Figure 4 This is a SEM image of Lactobacillus plantarum DY1 before embedding in this invention.

[0020] Figure 5 This is a SEM image of *Lactobacillus plantarum* DY1 after being embedded in the substrate according to the present invention.

[0021] Figure 6 This is an electron microscope image of the simulated gastric juice tolerance experiment of this invention.

[0022] Figure 7 This is an electron microscope image of the simulated intestinal fluid tolerance experiment of this invention.

[0023] Figure 8 This invention simulates the number of viable bacteria before and after probiotic encapsulation in a gastric juice tolerance experiment.

[0024] Figure 9This refers to the number of viable bacteria before and after probiotic encapsulation in the intestinal fluid tolerance experiment of this invention.

[0025] Figure 10 Serum and liver biochemical indicators and kidney inflammatory factor levels in mice of each group.

[0026] Figure 11 The Ace index represents the gut microbiota of mice in each group.

[0027] Figure 12 The Shannon index represents the gut microbiota of mice in each group.

[0028] Figure 13 Principal coordinate analysis (PCoA) of the gut microbiota in each group of mice.

[0029] Figure 14 The differences in gut microbiota at the phylum and genus levels among the groups of hyperuricemic mice were identified.

[0030] Figure 15 Enrichment of differential metabolite pathways in DY1 mice.

[0031] Figure 16 Enrichment of differential metabolite pathways in DY1@PLL mice.

[0032] Figure 17 Electron micrographs of Lactobacillus plantarum DY1 obtained under different embedding conditions in this invention before and after embedding.

[0033] Figure 18 The survival rate of encapsulated Lactobacillus plantarum DY1 was obtained under different encapsulation conditions according to the present invention. Detailed Implementation

[0034] The following examples further illustrate specific embodiments of the present invention. It should be noted that the specific embodiments described herein are merely for illustration and explanation and are not intended to limit the scope of the present invention.

[0035] This invention provides a simple and efficient encapsulation strategy to obtain probiotics co-encapsulated with polydopamine and polylysine, wherein polylysine is co-modified on the surface of the probiotics through the copolymerization of dopamine, thereby improving the survival rate of the probiotics in the gastrointestinal tract.

[0036] The results of the embodiments of this invention confirm that the embedded probiotics have the effect of lowering serum uric acid. This invention provides a method for preparing the embedded probiotics, an evaluation of their activity, and their application in the preparation of foods or medicines for the prevention and / or treatment of hyperuricemia. The invention will be described in detail below with reference to the embodiments.

[0037] The Lactobacillus plantarum DY1 used in the following examples was obtained through preliminary screening in the laboratory and is now deposited at the China General Microbiological Culture Collection Center with accession number CGMCC NO.28810.

[0038] Example 1: Encapsulation of probiotics and evaluation of their in vitro activity

[0039] 1.1 Encapsulation and Characterization of Probiotics

[0040] The activated *Lactobacillus plantarum* DY1 solution was inoculated into 2% MRS liquid medium and cultured at 37°C for 16 h. After centrifugation at 4000g for 5 min, the bacterial suspension was resuspended in pre-cooled, sterilized PBS. 1.5 × 10⁻⁶ 9 CFU bacteria were added to 1 mL of 10 mM Tris-HCl (pH 8.5) buffer containing 0.5 mg / mL dopamine. 50 μL of PLL solution (0.1 mg / mL) was added to the mixture, and the mixture was stirred at 200 rpm for 30–45 min at room temperature to promote polymer diffusion. After the reaction, centrifugation was performed to remove unpolymerized dopamine. The sediment was resuspended in Tris-HCl buffer (pH 8.5), and 50 μL of 0.1 mg / mL PLL solution was added again. The resulting product, DY1@PLL, was centrifuged, resuspended in sterile physiological saline, and stored at 4 °C. Figure 1 As shown, the embedded bacterial culture is gray. The cell morphology of DY1 and DY1@PLL was observed using transmission electron microscopy. Figure 2 Transmission electron microscopy images and Figure 3 Scanning electron microscopy images show that the surface of unencapsulated bacteria is smooth, while the surface of encapsulated bacteria has a granular nano-coating. This indicates that the bacteria were successfully encapsulated and their outer surface is equipped with a nano-coating.

[0041] 1.2, DY1@PLL is resistant to SGF, SIF, and high temperature.

[0042] We prepared simulated gastric juice (SGF) and simulated intestinal juice (SIF) according to the description in the United States Pharmacopeia (USP38-NF33). SGF: 16.4 mL of 1 mol / L diluted hydrochloric acid solution was added to 800 mL of distilled water, along with 10 g of pepsin. The mixture was thoroughly combined and transferred to a 1000 mL volumetric flask. The pH was adjusted to 2. SIF: 6.8 g of potassium dihydrogen phosphate was dissolved in 500 mL of distilled water, and the pH was adjusted to 6.8. 10 g of trypsin was dissolved in an appropriate amount of distilled water. The two solutions were mixed and transferred to a 1000 mL volumetric flask, with bile salts added to a concentration of 3 mg / mL. SGF and SIF were filtered through a 0.2 μm filter membrane. Equal volumes of DY1 and DY1@PLL were inoculated into SGF and SIF at a 10% inoculum, respectively, and incubated at 37°C. Samples were collected at 0 h, 1 h, 2 h, and 3 h, and the bacterial count was accurately determined using the dilution plate method. Take appropriate amounts of DY1 and DY1@PLL bacterial solutions and observe them using a transmission electron microscope. Figure 4 and Figure 5 As shown, DY1@PLL can resist the penetration of gastric and intestinal juices, thus maintaining the integrity of probiotics. Figure 6 As shown, after 3 hours of simulated gastric digestion, the encapsulated probiotics still retained a viable count of 7.63 ± 0.03 Log cfu / mL. The results of simulated intestinal digestion... Figure 7 The number of live probiotics with nano-coating was 7.63±0.03Log cfu / mL, which is 8.13 times that of probiotics without encapsulation.

[0043] Example 2: Evaluation of the treatment and mechanism of polydopamine and polylysine co-modified probiotics in mice with hyperuricemia.

[0044] 2.1 Treatment of uric acid

[0045] Six-week-old male Kunming mice were randomly divided into five groups (n=8 per group): control, model, free probiotic group (DY1), encapsulated probiotic group (DY1@PLL), and positive control group (allopurinol, AP). Except for the normal control group, the other groups were administered hypoxanthine (500 mg / kg) and potassium oxonate (PO) (250 mg / kg) daily. Blood samples were collected after a 15-day modeling period. Experiments were then continued by model creation and drug administration. On day 16, the model group, free probiotic group, encapsulated probiotic group, and positive control group were administered hypoxanthine (500 mg / kg) and PO (250 mg / kg), respectively, while the control group received 0.5% CMC-Na. One hour later, the free probiotic group was administered a 1×10⁻⁶ concentration of allopurinol. 9 DY1 bacterial suspension (1 mL) at cfu / mL was used to encapsulate probiotics at a concentration of 1×10⁻⁶. 9DY1@PLL bacterial suspension (1 mL, cfu / mL). The positive control group received allopurinol (10 mg / kg). Control and model mice were administered physiological saline by gavage. Treatment was administered once daily for 22 consecutive days. Mouse feces were collected and stored at -80°C for later use. Half an hour after the last administration, mice were anesthetized with sodium pentobarbital, and blood samples were collected. Mice were then sacrificed, and their liver, intestines, and kidneys were harvested. A portion of the liver from each mouse was placed in a 1.5 mL centrifuge tube filled with 4% paraformaldehyde for tissue embedding.

[0046] 2.2 Serum and Liver Biochemical Indicators

[0047] Serum uric acid, creatinine, and xanthine oxidase levels, as well as liver xanthine oxidase and adenosine dehydrogenase activities, were measured in mice strictly according to the kit instructions. Elevated UA levels are a major characteristic indicator of hyperuricemia. The results are shown in the figure. After 15 days of oral administration of hypoxanthine and intraperitoneal injection of potassium oxonate, the levels of uric acid, creatinine, and xanthine oxidase in mice were significantly improved. Figure 10 As shown in Figure B, the serum uric acid level in the model group showed a significant difference compared to the blank control group (P<0.05), indicating successful modeling and allowing for subsequent experiments. Figure 10 As shown in Figure C, after 22 days of administration, the uric acid level in the hyperuricemia model group was significantly higher than that in the blank control group. Compared with the model group, the uric acid levels in all treatment groups were significantly lower, and the encapsulated probiotics showed the best uric acid-lowering effect. XOD and ADA are key enzymes in uric acid metabolism. Figure 10 As shown in the DF, XOD levels in the serum and liver of mice in the model group were significantly higher than those in the control group, and significantly lower after drug administration compared to the model group. The trend of ADA levels in the liver was similar to that of XOD. Creatinine is a key indicator for evaluating the degree of kidney injury, such as... Figure 10 As shown in G, the group with encapsulated probiotics experienced the least degree of kidney damage.

[0048] 2.3 Measurement of IL-1β and TNF-α in renal tissue

[0049] The kidney tissue samples from each group were homogenized mechanically with 0.9% saline at 60 Hz for 1 min using a tissue homogenizer, and then centrifuged at 5000 rpm for 10 min to obtain the supernatant. The levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the tissue supernatant were determined using ELISA. The results are as follows: Figure 10 As shown in HI, IL-1β and TNF-α levels were significantly elevated in hyperuricemic mice. The levels of renal inflammatory factors were significantly reduced in the probiotic-encapsulated group.

[0050] 2.4. Intestinal flora analysis

[0051] Total DNA was extracted from each group of samples according to the DNA extraction kit instructions, and then the DNA was stored at -80°C. The bacterial 16S v3–v4 region was amplified using 338F and 806R. Library construction was performed using a rapid DNA-Seq kit. Sequences were obtained using the Illumina Miseq PE 300 platform. The obtained sequences were imported into Trimmomatic quality control and Flash software (v1.2.11) for sequence optimization. The optimized sequences were clustered using Uparse 7.0 software, achieving a similarity of 97%, resulting in operational taxonomic units (OTUs). Each sequence was labeled using a Bayesian algorithm-based RDP classifier, and then a species abundance table was generated based on the Silva database. Alpha diversity was characterized by Ace and Chao. Beta diversity at the OTU level was analyzed using PCoA. Microbiome analysis was performed using R software, with 5 samples per group. Figure 11 and Figure 12 As shown, α-diversity analysis revealed significantly enhanced Ace and Chao indices in the hyperuricemic mouse model compared to other groups, indicating higher diversity and abundance of the gut microbiota. β-diversity was used to elucidate the structure and function of the gut microbiota. Figure 13 As shown, principal component analysis (PCoA) based on unweighted unifracs revealed a significant separation between the model group and normal mice, indicating that the gut microbiota composition of hyperuricemic mice was disrupted. Further analysis was conducted to determine the differentially expressed microbiota between the model group and the pre- and post-embedding groups. Figure 14As shown, at the phylum level, compared with the model, DY1 and DY1@PLL treatments significantly reduced the abundance of Bacteroidetes and Campilobacterota, while the DY1 group significantly increased the abundance of Actinobacteria, and the DY1@PLL group significantly increased the abundance of Firmicutes. At the genus level, Lactobacillus was the most abundant in all groups. The abundance of lactic acid bacteria in each group was as follows: 41.20% in the control group, 18.28% in the model group, 50.53% in the DY1 group, and 77.49% in the DY1@PLL group. Both free probiotics and encapsulated probiotics increased the abundance of Lactobacillus in HUA mice, with the encapsulated probiotic group showing the greatest increase. In addition to changes in the abundance of Lactobacillus, there were also differences in the abundance of bacterial communities among different groups. Compared with the control, the abundance of Roseburia in the model was significantly higher than that in the control, while the abundance of Enterorhabdus and Parabacteroides was significantly lower than that in the control. This pattern is usually associated with hyperuricemia. Compared to the model, DY1@PLL significantly reduced the abundance of Bacteroides, Helicobacter, Lachnospiraceae_UCG-006, norank_f__Lachnospiraceae, Roseburia, and norank_f__norank_o__Clostridia_UCG-014. DY1 downregulated the abundance of Bacteroides, Helicobacter, norank_f_norank_o_clostridia_UCG-014, and... Roseburia The abundance of Enterorhabdus was increased.

[0052] 2.5 Metabolomics Studies Based on LC-MS / MS

[0053] After thawing at 4°C, 100 μL of serum was added to an EP tube. Subsequently, proteins were precipitated with methanol (300 μL), and 10 μL of internal standard (2-chlorophenylalanine) was added. All samples were thoroughly mixed to generate a quality control (QC) sample. LC-MS analysis was performed using a ThermoFisher Scientific UHPLC-QExactive HF-X system. The obtained data were then imported into ProgenesisQI, and metabolite identification was performed using the comprehensive databases HMDB (http: / / www.hmdb.ca / ) and METLIN (https: / / metlin.scripps.edu / ). The data matrix was imported into SIMCA 14.1 software for metabolite profiling analysis. Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to effectively visualize the differences in metabolites between different groups. Metabolites with p < 0.05 and VIP > 1 were identified as differentially metabolites. Subsequently, the KEGG database (https: / / www.genome.jp / kegg / ) was used to conduct enrichment analysis and research on metabolic pathways to further understand their biological functions. For example... Figure 15 and 16 As shown, pathway enrichment analysis confirmed that both DY1 and DY1@PLL are involved in tryptophan metabolism and purine metabolism, and both involve indoleacetaldehyde, 3-(3-indole)-2-oxypropionic acid, 3-indoleacetic acid, uric acid, xanthine, ADP, and adenosine monophosphate.

[0054] Comparative Example 1

[0055] Probiotics were prepared and characterized using PLL solutions with a concentration of 50 μg / mL and without PLL solution.

[0056] The activated *Lactobacillus plantarum* DY1 solution was inoculated into 2% MRS liquid medium and cultured at 37°C for 16 h. After centrifugation at 4000g for 5 min, the bacterial suspension was resuspended in pre-cooled, sterilized PBS. 1.5 × 10⁻⁶ 9 CFU bacteria were added to 1 mL of 10 mM Tris-HCl (pH 8.5) buffer containing 0.5 mg / mL dopamine. 50 μL of PLL solution (50 μg / mL) was added to the mixture, and the mixture was stirred at 200 rpm for 30-45 min at room temperature to promote polymer diffusion. After the reaction, centrifugation was performed to remove unpolymerized dopamine. The sediment was resuspended in Tris-HCl buffer (pH 8.5), and 50 μL of 0.05 mg / mL PLL solution was added again. The resulting product, DY1@PLL, was centrifuged, resuspended in sterile physiological saline, and stored at 4°C. DY1@PDA was obtained as described above, but without the addition of PLL. Figure 2 and Figure 17 As shown, cell morphology was observed using scanning electron microscopy. It was found that the cell surface morphology of DY1@PDA and DY1@PLL (0.05 mg / mL) was similar, with the surface covered with rough nanoparticles. However, DY1@PLL (0.1 mg / mL) had a smooth outer shell with many uniformly compacted nanoparticles embedded within. This indicates that PLL at a concentration of 0.05 mg / mL cannot co-deposit with PDA.

[0057] Comparative Example 2

[0058] Encapsulated probiotics with different PLL concentrations were prepared according to Example 1 and Comparative Example 1 above, and the survival rate of the probiotics was determined.

[0059] Plate counts were performed on DY1@PLL bacterial suspensions at PLL concentrations of 0, 0.1, 0.5, and 1 mg / mL, with free probiotics serving as a control. Survival rates were calculated. Figure 18 As shown, the survival rate was highest when the PLL concentration was 0.1 mg / mL. Therefore, the selected PLL concentration was 0.1 mg / mL.

[0060] Therefore, this invention utilizes specific dosages and conditions to promote polymer diffusion and form a nano-coating to encapsulate probiotics. The prepared probiotic nano-coating not only maintains cell viability but also protects probiotics from external damage, enhancing their tolerance to the gastrointestinal environment.

Claims

1. A method for encapsulating probiotics, characterized in that: The encapsulated probiotics are probiotics encapsulated in a coating; the coating is a mixture of polydopamine and polylysine. The probiotic is Lactobacillus plantarum, which is currently deposited at the China General Microbiological Culture Collection Center, with accession number CGMCC NO.28810. 1.5×10 9 CFU bacteria were added to 1 mL of 10 mM Tris-HCl buffer (pH 8.5) containing 0.5 mg / mL dopamine. 50 μL of 0.1 mg / mL PLL solution was added to the mixture. The mixture was stirred at 200 rpm for 30–45 min at room temperature to promote polymer diffusion. After the reaction, the mixture was centrifuged to remove unpolymerized dopamine. The precipitate was resuspended in Tris-HCl buffer (pH 8.5), and 50 μL of 0.1 mg / mL PLL solution was added again. The resulting product, DY1@PLL, was centrifuged, resuspended in sterile physiological saline, and stored at 4 °C.

2. A method for preparing encapsulated probiotics as described in claim 1, characterized in that: 1.5×10 9 CFU bacteria were added to 1 mL of 10 mM Tris-HCl buffer (pH 8.5) containing 0.5 mg / mL dopamine. 50 μL of 0.1 mg / mL PLL solution was added to the mixture. The mixture was stirred at 200 rpm for 30–45 min at room temperature to promote polymer diffusion. After the reaction, the mixture was centrifuged to remove unpolymerized dopamine. The sediment was resuspended in Tris-HCl buffer (pH 8.5), and 50 μL of 0.1 mg / mL PLL solution was added again. The resulting product, DY1@PLL, was centrifuged, resuspended in sterile physiological saline, and stored at 4 °C.

3. The application of the encapsulated probiotics as described in claim 1, characterized in that: The application of the encapsulated probiotic in the preparation of drugs for the prevention and / or treatment of hyperuricemia; wherein the probiotic is Lactobacillus plantarum, which is currently deposited at the China General Microbiological Culture Collection Center, with accession number CGMCC NO.28810; Encapsulated probiotics are probiotics that are coated with a coating; wherein the coating is a mixture of polydopamine and polylysine.

4. A bacterial agent for relieving hyperuricemia, characterized in that: Contains the encapsulated probiotics as described in claim 1.

Images